{"symbol":"ABBV","fiscalQuarter":"Q2-2026","reportDate":"2026-07-30","reportTime":"BMO","status":"upcoming","company":{"name":"AbbVie Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/ABBV/earnings/Q2-2026","preBrief":{"companySnapshot":"AbbVie Inc. is a global biopharmaceutical company focused on developing advanced therapies for complex diseases. With a market cap of $438 billion, it plays a significant role in the health care sector, particularly in biotechnology, addressing major health challenges through innovative treatments.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of profitability and will show how well AbbVie is managing its costs and generating income.","consensus":"N/A"},{"name":"Revenue Growth","why":"Revenue growth reflects the company's ability to expand its market presence and sales, which is crucial for long-term sustainability.","consensus":"N/A"}],"lastQuarterRecap":{"summary":"In Q1 2026, AbbVie reported an EPS of $2.65, slightly beating expectations. The stock reacted positively, gaining 3.14% the following day.","promises":[]},"wallStreetExpectations":{"summary":"Overall, expectations for AbbVie are mixed, with some analysts anticipating continued strong performance while others are cautious due to recent revenue fluctuations.","bullCase":"The optimistic view hinges on AbbVie continuing its trend of beating EPS estimates, which could signal robust demand for its products and effective cost management.","bearCase":"Conversely, concerns about potential revenue declines or increased competition in the biotechnology space could lead to a disappointing earnings report."},"optionsSignal":{"impliedMove":"5.85%","context":"The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+1.30%","reaction":"+3.14%"},{"quarter":"Q4-2025","epsSurprise":"+2.03%","reaction":"-3.79%"},{"quarter":"Q3-2025","epsSurprise":"+4.91%","reaction":"-4.45%"},{"quarter":"Q2-2025","epsSurprise":"-8.39%","reaction":"-0.15%"},{"quarter":"Q1-2025","epsSurprise":"+2.93%","reaction":"+3.15%"}],"pivotalQuestions":[{"question":"What will the EPS be this quarter, and how does it compare to previous quarters?","whyItMatters":"Given AbbVie's history of beating EPS estimates, this figure will be crucial for investor confidence and stock performance."},{"question":"How is AbbVie addressing competition in the biotechnology sector?","whyItMatters":"Understanding AbbVie's strategy against competitors will provide insights into its future growth potential and market position."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $2.70 or higher would confirm strong operational performance and market demand.","bearTrigger":"An EPS below $2.60 could indicate underlying issues with product sales or market share.","context":"The core debate this quarter revolves around AbbVie's ability to maintain profitability in a competitive environment."},"scenarioPlaybook":{"beatAndRaise":"If AbbVie beats expectations, history suggests the stock could rise by around 1.78%, confirming strong demand and management effectiveness.","inLineCautious":"If results are in line with expectations but management provides cautious commentary, the stock may experience muted movement as investors reassess.","miss":"A miss on EPS could lead to a decline of about 0.15%, reflecting disappointment and potential concerns about future growth."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating AbbVie's ability to outperform due to its strong pipeline and recent product launches.","supportingPoints":["AbbVie has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.","The options market is pricing in a larger move than historical averages, suggesting heightened expectations.","Recent product developments could drive unexpected revenue growth not reflected in current estimates."],"riskToConsensus":"If AbbVie reports an EPS significantly above $2.70, it could challenge the current cautious sentiment."},"whatToListenFor":["Any updates on new product launches and their expected impact on revenue.","Insights into cost management strategies and their effect on profitability.","Discussion on competitive pressures and how AbbVie plans to address them.","Management's outlook on future revenue growth and market expansion.","Any changes in guidance or expectations for the next quarter."],"metaDescription":"AbbVie (ABBV) reports Q2 2026 earnings July 30. Analysts expect key insights on EPS and revenue growth amid competitive pressures."}}